Trk Receptor

Tropomyosin related kinase receptor

Trk receptors are a family of three receptor tyrosine kinases (TrkA, TrkB, and TrkC), each of which can be activated by one or more of four neurotrophins-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4).

TrkA, TrkB, and TrkC are transmembrane proteins that comprise the TRK receptor family. These receptor tyrosine kinases are expressed in human neuronal tissue, and play an essential role in both the physiology of development and function of the nervous system through activation by neurotrophins (NTs). The latter are specific ligands known as NGF for TrkA, BDGF, and NT-4/5 for TrkB and NT3 for TrkC, respectively.

The binding of the ligand to the receptor triggers the oligomerisation of the receptors and phosphorylation of specific tyrosine residues in the intracytoplasmic kinase domain. This event results into the activation of signal transduction pathways leading to proliferation, differentiation and survival in normal and neoplastic neuronal cells.

Trk Receptor Inhibitors, Agonists, Activators & Antagonists

(R)-Larotrectinib

((R)-LOXO-101; (R)-ARRY-470)

Cat. No.: HY-12866B

(R)-Larotrectinib is a potent **TRK** inhibitor with an IC_{50} value of 28.5 nM for TrkA. (R)-Larotrectinib can be used for researching cancer, inflammatory and certain infectious diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7,8-Dihydroxyflavone

Cat. No.: HY-W013372

7,8-Dihydroxyflavone is a potent and selective **TrkB** agonist that mimics the physiological actions of Brain-derived neurotrophic factor (BDNF). Displays therapeutic efficacy toward various neurological diseases.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Altiratinib

(DCC-2701)

Cat. No.: HY-B0791

Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC_{50}s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for **MET**, **TIE2**, **VEGFR2**, **FLT3**, **Trk1**, **Trk2**, and **Trk3** respectively.



Purity: 98.06%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amitriptyline hydrochloride

Cat. No.: HY-B0527A

Amitriptyline hydrochloride is an inhibitor of **serotonin reuptake transporter (SERT)** and **noradrenaline reuptake transporter (NET)**, with K_is of 3.45 nM and 13.3 nM for human SERT and NET, respectively.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Amitriptyline-d3 hydrochloride

Cat. No.: HY-135096

Amitriptyline-d3 hydrochloride is the deuterium labeled Amitriptyline (hydrochloride).



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 1 mg, 5 mg, 10 mg

Amitriptyline-d6 hydrochloride

Cat. No.: HY-B0527AS

Amitriptyline-d6 hydrochloride is the deuterium labeled Amitriptyline hydrochloride.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 1 mg, 5 mg, 25 mg

ANA-12

Cat. No.: HY-12497

ANA-12 is a potent and selective **TrkB** antagonist with IC_{50}s of 45.6 nM and 41.1 μM for the high and low affinity sites, respectively.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

AZ-23

(AZ23; AZ 23)

Cat. No.: HY-15590

AZ-23 is an ATP-competitive and orally bioavailable **Trk kinase A/B/C** inhibitor with IC_{50}s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.



Purity: 98.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Belizatinib

(TSR-011)

Cat. No.: HY-17603

Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC_{50} of 0.7nM for wild-type recombinant ALK kinase.



Purity: 99.66%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CE-245677

Cat. No.: HY-112423

CE-245677 is a potent reversible inhibitor of **Tie2** and **TrkA/B** kinases with a cellular IC_{50}s of 4.7 and 1 nM.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CH7057288

Cat. No.: HY-107362

CH7057288 is a potent and selective **TRK** inhibitor.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cyclotraxin B

Cat. No.: HY-P1178

Cyclotraxin B, a cyclic peptide, is a highly potent and selective **TrkB** inhibitor without altering the binding of BDNF. Cyclotraxin B non-competitively inhibits BDNF-induced **TrkB** activity with an IC_{50} of 0.30 nM.

Purity: 99.87%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cyclotraxin B TFA

Cat. No.: HY-P1178A

Cyclotraxin B TFA, a cyclic peptide, is a highly potent and selective **TrkB** inhibitor without altering the binding of BDNF. Cyclotraxin B TFA non-competitively inhibits BDNF-induced **TrkB** activity with an IC_{50} of 0.30 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

D5261

Cat. No.: HY-144690

D5261 is a potent, type Ⅲ allosteric **tropomyosin-related kinase A (TrkA)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DS-1205b free base

Cat. No.: HY-114357A

DS-1205b free base is a potent and selective inhibitor of **AXL kinase**, with an IC_{50} of 1.3 nM. DS-1205b free base also inhibits **MER**, **MET**, and **TRKA**, with IC_{50}s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Entrectinib

(NMS-E628; RXDX-101)

Cat. No.: HY-12678

Entrectinib (NMS-E628) is a potent, orally available, and CNS-active **pan-Trk**, **ROS1**, and **ALK** inhibitor. Entrectinib inhibits TrkA, TrkB, TrkC, ROS1 and ALK with IC_{50} values of 1, 3, 5, 12 and 7 nM, respectively. Antitumor activity.



Purity: 99.32%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FLT3/TrKA-IN-1

Cat. No.: HY-146749

FLT3/TrKA-IN-1 is a potent **FLT3/TrKA** dual kinase inhibitor with the IC_{50}s of 43.8 nM, 97.2 nM, 92.5 nM and 23.6 nM for FLT3, FLT3-ITD, FLT3-TKD and TrKA, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GNF-5837

Cat. No.: HY-13491

GNF-5837 is a potent, selective, and orally bioavailable pan-**tropomyosin receptor kinase (TRK)** inhibitor which display antiproliferative effects in cellular Ba/F3 assays (IC_{50} values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteins **Tel-TrkC**, **Tel-TrkB** and...



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GNF-8625 monopyridin-N-piperazine hydrochloride

Cat. No.: HY-131706A

GNF-8625 monopyridin-N-piperazine hydrochloride (TRKi-2), a TRK inhibitor, which is from the patent WO 2020038415 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW 441756

Cat. No.: HY-18314

GW 441756 is a potent and specific nerve growth factor (NGF) receptor tyrosine kinases A (**TrkA**) inhibitor (IC_{50}=2 nM), which eliminates the BmK NSPK-induced neurite outgrowth.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

hTrkA-IN-1

Cat. No.: HY-136535

hTrkA-IN-1 is a potent and orally active inhibitor of **TrkA kinase** with an IC_{50} of 1.3 nM, compound 2. extracted from patent WO2015175788. hTrkA-IN-1 can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IHMT-TRK-284

Cat. No.: HY-146697

IHMT-TRK-284 (Compound 34) is a potent, orally active **type II TRK kinase** inhibitor with IC_{50} values of 10.5, 0.7, and 2.6 nM to **TRKA, B**, and **C** respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

K-252a

(SF2370; Antibiotic K 252a; Antibiotic SF 2370)

Cat. No.: HY-N6732

K-252a, a staurosporine analog, inhibits **protein kinase**, with IC_{50} values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca^{2+}/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Larotrectinib

(LOXO-101; ARRY-470)

Cat. No.: HY-12866

Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase **(TRK)** family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Larotrectinib sulfate

(LOXO-101 sulfate; ARRY-470 sulfate)

Cat. No.: HY-12866A

Larotrectinib sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase **(TRK)** family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).



Purity: 99.57%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Larotrectinib-d7

(LOXO-101-d7; ARRY-470-d7)

Cat. No.: HY-12866S

Larotrectinib-d7 (LOXO-101-d7) is the deuterium labeled Larotrectinib.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lestaurtinib

(CEP-701; KT-5555)

Cat. No.: HY-50867

Lestaurtinib (CEP-701;KT-5555) is an ATP-competitive multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases. Lestaurtinib inhibits **JAK2**, **FLT3** and **TrkA** with IC_{50}s of 0.9, 3 and less than 25 nM, respectively.



Purity: 99.92%
Clinical Data: Phase 3
Size: 5 mg

LM22A-4

Cat. No.: HY-100673

LM22A-4 is a specific agonist of **tyrosine kinase receptor B**, used for neurological disease research.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LM22B-10

Cat. No.: HY-104047

LM22B-10 is an activator of **TrkB/TrkC** neurotrophin receptor, and can induce **TrkB**, **TrkC**, **AKT** and **ERK** activation in vitro and in vivo.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

LPM4870108

Cat. No.: HY-132229

LPM4870108 is a potent and orally active **pan-Trk (WT and MT)** inhibitor, with IC_{50}s of 0.2 nM, 2.4 nM, 3.5 nM and 2.3 nM for **TrkC**, **TrkA**, **TrkA^{G595R}** and **TrkA^{G667C}**, respectively. LPM4870108 shows selectivity for Trk over ALK (IC_{50}=182 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

N-Acetyl-5-hydroxytryptamine

(N-Acetylserotonin; Normelatonin; O-Demethylmelatonin) Cat. No.: HY-107854

N-Acetyl-5-hydroxytryptamine is a Melatonin precursor, and that it can potently activate **TrkB** receptor.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

N-Acetyl-5-hydroxytryptamine-d3 (N-Acetylserotonin-d3;

Normelatonin-d3; O-Demethylmelatonin-d3) Cat. No.: HY-107854S

N-Acetyl-5-hydroxytryptamine-d3 (N-Acetylserotonin-d3) is the deuterium labeled N-Acetyl-5-hydroxytryptamine.
N-Acetyl-5-hydroxytryptamine is a Melatonin precursor, and that it can potently activate **TrkB** receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ONO-7475

Cat. No.: HY-114358

ONO-7475 is a potent, selective, and orally active **Axl/Mer** inhibitor with IC_{50} values of 0.7 nM and 1.0 nM, respectively. ONO-7475 sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells.



Purity: 99.38%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Paltimatrectinib

Cat. No.: HY-145587

Paltimatrectinib (compound I-147) is a potent **tyrosine kinase** inhibitor with an IC_{50} of <10 nM for tropomyosin kinases A (TrkA). Paltimatrectinib has the potential for cancer and inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pan-Trk-IN-2

Cat. No.: HY-144028

Compound cpd-1 is a small molecule **Trks** inhibitor with good antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pan-Trk-IN-3

Cat. No.: HY-144069

Pan-Trk-IN-3 (Compound 11g) is a potent inhibitor of pan-**Trk** and their drug-resistant mutants with IC_{50} values of 2, 3, 2, 21, 26, 5, 7 and 6 nM against **TrkA**, **TrkB**, **TrkC**, **TrkA**^{G595R}, **TrkA**^{G667C}, **TrkA**^{G667S}, **TrkA**^{F589L} and **TrkC**^{G623R}, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06273340

Cat. No.: HY-122616

PF-06273340 is a potent, selective, orally bioavailable and peripherally restricted pan **Trk** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06733804

Cat. No.: HY-112434

PF-06733804 is a potent **pan-Trk** inhibitor in cell-based assays with IC_{50}s of 8.4 nM, 6.2 nM and 2.2 nM for **TrkA**, **TrkB** and **TrkC**, respectively. Anti-hyperalgesic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06737007

Cat. No.: HY-112437

PF-06737007 is a potent **pan-Trk** inhibitor in cell-based assays with IC_{50}s of 7.7 nM, 15 nM and 3.9 nM for **TrkA**, **TrkB** and **TrkC**, respectively. Anti-hyperalgesic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-6683324

(Trk-IN-4) Cat. No.: HY-112436

PF-6683324 (Trk-IN-4) is a potent **pan-Trk** inhibitor in cell-based assays with IC_{50}s of 1.9 nM, 2.6 nM and 1.1 nM for **TrkA**, **TrkB** and **TrkC**, respectively. Anti-hyperalgesic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Repotrectinib

(TPX-0005) Cat. No.: HY-103022

Repotrectinib (TPX-0005) is a potent **ROS1** (IC_{50}=0.07 nM) and **TRK** (IC_{50}=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT **ALK** (IC_{50}=1.01 nM). Repotrectinib has anti-cancer activity.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Selitrectinib

(LOXO-195) Cat. No.: HY-101977

Selitrectinib (LOXO-195) is a next-generation **TRK kinase** inhibitor, with IC_{50}s of 0.6 nM and <2.5 nM for **TRKA** and **TRKC**, respectively.



Purity: 99.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sitravatinib

(MGCD516; MG-516) Cat. No.: HY-16961

Sitravatinib (MGCD516) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: 99.59%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Sitravatinib malate

(MGCD516 malate; MG-516 malate) Cat. No.: HY-16961A

Sitravatinib malate (MGCD516 malate) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Tavilermide

(MIM-D3) Cat. No.: HY-17622

Tavilermide is a selective, partial agonist of **TrkA**, or a nerve growth factor (NGF) mimetic.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

TIY-7

Cat. No.: HY-146755

TIY-7 is a selective and orally active **tropomyosin receptor kinase (TRK)** inhibitor. TIY-7 shows enzyme inhibitory activity with IC_{50}s of 2.9, 1.1, 0.7, 0.8, 0.8, 0.2 nM for TRKA, $TRKA^{G595R}$, $TRKA^{G667C}$, $TRKA^{F589L}$, $TRKC^{G623R}$, $TRKC^{G696A}$, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trk-IN-1

Cat. No.: HY-12327

Trk-IN-1 (example 9), a potent **tropomyosin-related kinase (Trk)** inhibitor, shows potency against TrkA (3.7 nM) and TrkB (94 nM), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trk-IN-10

Cat. No.: HY-144423

Trk-IN-10 (Compound 14j) is a potent inhibitor of **TRK** (IC_{50} = 0.86, 6.92 nM, against TrkA, $TrkA^{G595R}$, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key drug target in solid tumors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trk-IN-11

Cat. No.: HY-144424

Trk-IN-11 (Compound 14h) is a potent inhibitor of **TRK** (IC_{50} = 1.4, 1.8 nM, against TrkA, $TrkA^{G595R}$, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key drug target in solid tumors. Trk-IN-11 has the potential for the research of cancer disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-12

Cat. No.: HY-144451

TRK-IN-12 (Compound 9e) is a potent inhibitor of **TRK** (TRK^{G595R} IC_{50} = 13.1 nM). TRK-IN-12 is a macrocyclic derivative compound. TRK-IN-12 shows significant antiproliferative activity in the Ba/F3-LMNA-NTRK1 cell line (IC_{50} = 0.080 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-13

Cat. No.: HY-146518

TRK-IN-13 is a potent inhibitor of **TRK**. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-14

Cat. No.: HY-146519

TRK-IN-14 is a potent inhibitor of **TRK**. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-15

Cat. No.: HY-146521

TRK-IN-15 is a potent inhibitor of **TRK**. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-16

Cat. No.: HY-146522

TRK-IN-16 is a potent inhibitor of **TRK**. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-17

Cat. No.: HY-146523

TRK-IN-17 is a potent inhibitor of **TRK**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-18

Cat. No.: HY-146524

TRK-IN-18 is a potent inhibitor of **TRK**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK-IN-19

Cat. No.: HY-146115

TRK-IN-19 (Compound I-10) is a potent inhibitor of **TRK** (TRKA IC_{50} = 1.1 nM, $TRKA^{G595R}$ IC_{50} = 5.3 nM). TRK-IN-19 has the potential for the research of cancer diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trk-IN-6

Cat. No.: HY-139891

Trk-IN-6 shows excellent in vitro potency on a panel of **TRK** mutants (IC_{50} = 0.2-0.7 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trk-IN-7

Cat. No.: HY-143557

Trk-IN-7 (compound I-6) is a potent **TRK** inhibitor with IC_{50}s of ranging from 0.25-10 nM for TRKA, TRKB and TRKC, respectively. Trk-IN-7 shows inhibition against EML4-ALK (IC_{50}<15 nM) ALK G1202R, ALK C1156Y, ALK R1275Q, ALK F1174L, ALK L1197M, and ALK G1269A (IC_{50}=5-50 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trk-IN-8

Cat. No.: HY-143561

Trk-IN-8 is a potent **TRK** inhibitor with IC_{50}s of 0.42, 0.89 and 1.5 nM for TRKAa, TRKA(G595R) and TRKC(G623R), respectively (WO2021115401A1, compound 3).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trk-IN-9

Cat. No.: HY-144321

Trk-IN-9 (Compound 12) is a potent inhibitor of **TRK**. Trk-IN-9 inhibits the proliferation of Km-12 cell lines. Trk-IN-9 induces the **apoptosis** of Km-12 cells in a concentration-dependent manner. Trk-IN-9 inhibits the phosphorylation of TRK to block downstream pathways.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRK/ALK-IN-1

Cat. No.: HY-144732

TRK/ALK-IN-1 (compound 21) is a potent and dual inhibitor of **TRK** and **ALK**. TRK/ALK-IN-1 in the enzymatic assays is in good accordance with anti-proliferative activity with IC_{50} values of 2.2, 9.3 and 38 nM towards TRKA, ALK^{WT} and ALK^{L1196M}, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TrkA-IN-1

Cat. No.: HY-129634

TrkA-IN-1 is a potent and selective **Tropomyosin-related kinase A (TrkA)** inhibitor with an IC_{50} of 99 nM in a cell-based assay. TrkA-IN-1 has analgesic activity.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Tyrphostin AG 879

(AG 879)

Cat. No.: HY-20878

Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits **TrkA** phosphorylation (IC_{50} of 10 μM), but not TrkB and TrkC.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg